National Institute for Health and Care Excellence gives green light to Darzalex® (daratumumab) with lenalidomide and dexamethasone for patients with n

Daratumumab combination is recommended for use within the NHS in England and Wales for treating adults with newly diagnosed multiple myeloma where a stem cell transplant is unsuitableEligible patients throughout England and Wales can now access alternative combination treatment option which has been shown to delay d...

Related Keywords

United Kingdom ,High Wycombe ,Buckinghamshire ,Scotland ,Amanda Cunnington ,Shelagh Mckinlay ,Scottish Medicines Consortium ,National Institute For Health ,Health Affairs ,Janssen Pharmaceutical Companies Of Johnson ,Cancer Research United Kingdom ,European Medicines Agency ,Janssen Pharmaceutical Companies ,National Institute ,Care Excellence ,Myeloma United Kingdom ,Final Draft Guidance ,Senior Director ,Patient Access ,Final Draft ,Research United ,Stem Cell Transplantation ,Multiple Myeloma ,Darzalex Assessment Report ,Plus Lenalidomide ,Versus Lenalidomide ,Transplant Ineligible Patients ,Newly Diagnosed Multiple Myeloma ,Clinical Assessment ,Key Subgroups ,